Clarity Pharmaceuticals Ltd. (AU:CU6)
ASX:CU6
Want to see AU:CU6 full AI Analyst Report?
CU6 Stock Chart & Stats
AU$3.13
-AU$0.24(-5.69%)
At close: 4:00 PM EST
AU$3.13
-AU$0.24(-5.69%)
Day’s Range― - ―
52-Week RangeAU$1.97 - AU$5.87
Previous CloseN/A
Volume1.66M
Average Volume (3M)3.27M
Market Cap
AU$768.32M
Enterprise ValueAU$702.45M
Total Cash (Recent Filing)AU$226.25M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Aug 26, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding372,971,220
10 Day Avg. Volume4,406,737
30 Day Avg. Volume3,266,690
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)8.84
Price to Sales (P/S)84.33
P/FCF Ratio-14.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$7.46Price Target Upside138.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.29
Revenue Forecast (FY)AU$3.25M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure materially lowers financial risk and eliminates interest burdens, giving management lasting flexibility to allocate capital to R&D and clinical programs. Over 2–6 months this improves solvency resilience and bargaining power for non-debt funding or partnerships.
Very High Gross MarginsNear-100% gross margins reflect a product profile with low COGS versus pricing power. Structurally, high gross margins provide significant operating leverage: if clinical programs commercialize, revenue scale can translate into durable margin-driven profit expansion despite fixed R&D and SG&A overheads.
Specialized Copper Theranostics PipelineA focused pipeline in copper-based theranostics establishes specialized scientific expertise and IP potential in a differentiated oncology niche. This positioning supports durable competitive advantages, partnership interest from academic/clinical centers, and a clearer commercial pathway if trials meet endpoints.
Bears Say
Widening Operating LossesPersistent and expanding operating losses steadily erode capital and force management into recurrent fundraising or deal-making. Over months this reduces runway, increases execution risk for clinical programs, and delays any sustainable path to self-funded commercialization without further dilution.
Negative Cash Flow And Rising BurnContinual negative operating and free cash flow indicate structural cash burn tied to development activities. This creates dependence on external financing or partnerships, elevating dilution risk and potentially forcing suboptimal timing or terms for capital raises that impair long-term shareholder value.
Declining Equity / Dilution RiskA shrinking equity base signals cumulative losses and prior financing, reducing financial flexibility. Over a multi-month horizon this heightens likelihood of additional dilutive raises or less favorable partnership economics, constraining strategic options for late-stage development or commercialization.
Clarity Pharmaceuticals Ltd. News
CU6 FAQ
What was Clarity Pharmaceuticals Ltd.’s price range in the past 12 months?
Clarity Pharmaceuticals Ltd. lowest share price was AU$1.97 and its highest was AU$5.87 in the past 12 months.
What is Clarity Pharmaceuticals Ltd.’s market cap?
Clarity Pharmaceuticals Ltd.’s market cap is AU$768.32M.
When is Clarity Pharmaceuticals Ltd.’s upcoming earnings report date?
Clarity Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 75 days.
How were Clarity Pharmaceuticals Ltd.’s earnings last quarter?
Clarity Pharmaceuticals Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.153 earnings per share for the quarter, missing the consensus estimate of -AU$0.083 by -AU$0.07.
Is Clarity Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Clarity Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Clarity Pharmaceuticals Ltd. pay dividends?
Clarity Pharmaceuticals Ltd. does not currently pay dividends.
What is Clarity Pharmaceuticals Ltd.’s EPS estimate?
Clarity Pharmaceuticals Ltd.’s EPS estimate is -0.15.
How many shares outstanding does Clarity Pharmaceuticals Ltd. have?
Clarity Pharmaceuticals Ltd. has 372,971,220 shares outstanding.
What happened to Clarity Pharmaceuticals Ltd.’s price movement after its last earnings report?
Clarity Pharmaceuticals Ltd. reported an EPS of -AU$0.153 in its last earnings report, missing expectations of -AU$0.083. Following the earnings report the stock price went up 0.278%.
Which hedge fund is a major shareholder of Clarity Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:CU6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clarity Pharmaceuticals Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$7.46 (138.18% Upside)
AU$7.46 (138.18% Upside)
Blogger Sentiment
Bullish
AU:CU6 Sentiment 89%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth AU$1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.03%
12-Months-Change
Fundamentals
Return on Equity
-59.59%
Trailing 12-Months
Asset Growth
86.54%
Trailing 12-Months
Company Description
Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd. is a clinical-stage company focused on developing innovative radiopharmaceutical products that serve as both diagnostic imaging tools and therapeutic agents for cancer treatment in both children and adults. Its primary offering is SARTATE, a targeted theranostic radiopharmaceutical specifically engineered for the diagnosis, staging, and treatment of cancers characterized by somatostatin receptor 2 expression. The company's developmental portfolio also includes SAR-Bombesin, a pan-cancer theranostic designed for tumors expressing the gastrin-releasing peptide receptor. Additionally, they are developing SAR-bisPSMA, a theranostic radiopharmaceutical specifically aimed at cancers exhibiting prostate-specific membrane antigen, facilitating their diagnosis, staging, and treatment. Clarity Pharmaceuticals further collaborates with the GU Research Network on the investigator-initiated X-Calibur trial, which investigates the use of 64Cu-SAR-bisPSMA in patients with known or suspected prostate cancer. Founded in 2010, the company is headquartered in Sydney, Australia.
CU6 Stock 12 Month Forecast
Average Price Target
AU$7.46
▲(138.18% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Immutep Ltd
―
Telix Pharmaceuticals
―
PYC Therapeutics Limited
―
Botanix Pharmaceuticals Limited
―
Options Prices
Currently, No data available
---